Liminatus Pharma (LIMN) Accumulated Expenses (2024 - 2025)
Liminatus Pharma (LIMN) posted Accumulated Expenses of $1060.0 for Q1 2025, up 31.68% sequentially from $805.0 in Q4 2024.
Liminatus Pharma (LIMN) Accumulated Expenses (2024 - 2025) Analysis & Trends
Liminatus Pharma has reported Accumulated Expenses for 2 years, with the latest figure at $1060.0 in Q1 2025.
- Quarterly Accumulated Expenses changed N/A year-over-year to $1060.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $1060.0 (changed N/A YoY) and the FY2024 annual result came in at $805.0, changed N/A from the prior year.
- Accumulated Expenses advanced to $1060.0 in Q1 2025 per LIMN's latest filing, from $805.0 in the prior quarter.
- Over five years, Accumulated Expenses peaked at $1060.0 in Q1 2025 and troughed at $805.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Liminatus Pharma | 256.03 Mn | 256.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 1,060.00 |
| Dec 31, 2024 | 805.00 |